Psilocybin 5 mg

DRUG3 trials

Sponsors

King's College London, Usona Institute, Nicky Mehtani, MD, MPH

Conditions

Autism Spectrum DisorderDepressive Disorder, MajorHuman Immunodeficiency Virus (HIV)Methamphetamine Use Disorder

Phase 2

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

Not yet recruitingNCT07756736

Nicky Mehtani, MD, MPHMethamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)

Start: 2026-11-01End: 2029-06-01Target: 30Updated: 2026-08-11

Phase 3

Psilocybin for Major Depressive Disorder (MDD)

Active, not recruitingNCT06308653

Usona InstituteDepressive Disorder, Major

Start: 2024-03-13End: 2027-01-30Updated: 2026-07-23

Unknown Phase

Psilocybin in Adults With and Without Autism Spectrum Disorder

CompletedNCT05651126

King's College LondonAutism Spectrum Disorder

Start: 2022-12-12End: 2024-08-23Updated: 2025-07-28

Related Papers

The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin.

2024-04-251 citations